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Abstract
Objective In literature, a great diversity of limited sampling
strategies (LSS) have been recommended for tacrolimus
monitoring, however proper validation of these strategies to
accurately predict the area under the time concentration
curve (AUC0–12) is limited. The aim of this study was to
determine whether these LSS might be useful for AUC
prediction of other patient populations.
Methods The LSS from literature studied were based on
regression equations or on Bayesian fitting using
MWPHARM 3.50 (Mediware, Groningen, the Netherlands).
The performance was evaluated on 24 of these LSS in our
population of 37 renal transplant patients with known AUCs.
The results were also compared with the predictability of the
regression equation based on the trough concentrations C0
and C12 of these 37 patients. Criterion was an absolute
prediction error (APE) that differed less than 15% from the
complete AUC0–12 calculated by the trapezoidal rule.
Results Thirteen of the 18 (72%) LSS based on regression
analysis were capable of predicting at least 90% of the 37
individual AUC0–12 within an APE of 15%. Additionally, all
but three LSS examined gave a better prediction of the
complete AUC0–12 in comparison with the trough concen-
trations C0 or C12 (mean 62%). All six LSS based on
Bayesian fitting predicted <90% of the 37 complete AUC0–12
correctly (mean 67%).
Conclusions The present study indicated that implement-
ation of LSS based on regression analysis could produce
satisfactory predictions although careful evaluation is
necessary.
Keywords Tacrolimus.Limitedsamplingstrategy.
Troughlevel.AUC0–12
Introduction
The calcineurin-inhibitor tacrolimus, used widely after
organ transplantation, has a narrow therapeutic index and
highly variable pharmacokinetic characteristics. Close
monitoring of the drug concentration is required to achieve
an optimum efficiency by minimizing the risk of subther-
apeutic and toxic blood concentrations. Efficacy and side
effects of tacrolimus are highly correlated with the area under
the time concentration curve (AUC0–12)[ 1]. Elevated tacro-
limus concentrations may lead to severe side effects such as
nephrotoxicity, neurotoxicity and hyperglycaemia [2–4],
while subtherapeutic tacrolimus concentrations increase the
risk of transplant rejection enormously [5–7].
The most exact way to monitor the total tacrolimus
exposure is by creating 12-h pharmacokinetic profiles,
which implies that the tacrolimus concentration should be
measured at at least six different time points. The AUC0–12
can then be calculated according to the trapezoidal rule
using the tacrolimus concentrations measured at different
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Munich, Germanytime points. Since recording a complete 12-h pharmacoki-
netic profile for every patient is not feasible in clinical
practice, traditionally many transplant centres have used
tacrolimus trough (C0) concentrations to estimate the
tacrolimus exposure. Although tacrolimus C0 concentra-
tions are generally considered to be a good indication of the
total systemic drug exposure [1, 8], its usefulness in
differentiating graft rejection episodes from nephrotoxicity
has been questioned [6, 9–11]. Recently, the correlation
between individual tacrolimus concentrations and AUC0–12
has been studied in kidney [12–18], liver [19], heart [20,
21] and lung [22] transplant recipients. In these studies, a
poor association was found between the tacrolimus C0
concentrations and the AUC0–12, while tacrolimus concen-
trations measured at other time points showed much better
correlations with the AUC0–12. Additionally, strategies have
been developed that included a limited number of sampling
time points within a short time post-dose, the so-called
limited sampling strategies (LSS). Several two- and three-
time-point sampling strategies showed a high correlation
with the AUC0–12 in published studies and were able to
predict the AUC0–12 more accurately than the C0 concen-
tration alone [12, 15–18, 20, 22].
Based on the number of published studies regarding LSS
for tacrolimus, there seems to be a growing interest for non-
C0 concentration measurements as an indicator of between-
patient variability and as a guide for dose adjustments.
Most of these studies recommend different LSS, but these
strategies have not been validated with an independent
population. Ting et al. [23] recently reported that validation
of the different LSS with an independent transplant
population is an absolute prerequisite. The question was
whether the LSS described in literature could be used in
other centres with different populations. Predictive value of
LSS from literature was evaluated using our own renal
post-transplant group of 37 patients with known AUCs.
Also the predictive value of trough levels (C0 and C12)
determined in our own population was investigated.
Materials and methods
Patient population
In total, 37 Caucasian renal transplant recipients for whom
a complete 12-h time tacrolimus concentration curve had
been determined in a past clinical trial were included in this
study (Table 1). The transplant recipients underwent a renal
transplantation at least 1 year ago. Patients taking medica-
tion known to interact with tacrolimus, who suffered from
gastro-intestinal or liver disease, pre-transplantation diabe-
tes mellitus or other disorders that could have altered the
absorption of tacrolimus were excluded from this study as
illustrated in Table 1.
Prior to the blood sample collection, there was no
tacrolimus dose change for at least 1 week. After overnight
fasting, the blood samples were collected immediately
before (C0) and 0.5 (C0.5), 1 (C1), 2 (C2), 3 (C3), 4 (C4),
5( C 5), 7.5 (C7.5) and 12 (C12) h after the morning
tacrolimus administration. Patients were not allowed to
take food until 1 h after ingesting the tacrolimus dose and
were advised to avoid grapefruit intake to prevent alter-
ations in the tacrolimus metabolism. Demographic as well
Table 1 Demographic characteristics of renal-transplant recipients
Demographic characteristics Patients
(n=37)
Gender (male/female) 24/13
Age (years, mean±SD) 51.3±10.9
Length (cm, mean±SD) 174±8.4
Weight (kg, mean±SD) 77.4±13.5
Body mass index (kg/m
2, mean±SD) 25.6±3.42
Primary kidney disease (n)
Glomerulonephritis 1
Chronic pyelonephritis 2
IgA nephropathy 4
Hypertensive nephropathy 7
Diabetes mellitus nephropathy 0
Polycystic kidney disease 8
Unknown 4
Other 11
Transplantation number (n)
First 30
Second 6
Third or more 1
Tacrolimus mono therapy (n)2 9
Tacrolimus dose (mg kg
−1 day
−1, mean±SD) 0.054±0.029
C0 (ng/mL, mean±SD) 6.59±1.39
AUC0–12 (ng×h/mL, mean±SD) 122.5±31.1
Cmax (ng/mL, mean±SD) 20.9±6.5
Tmax (h, mean±SD) 1.24±0.43
Use of azothioprine/MMF/rapamycine/steroids 3/4/0/2
Time since transplantation (days, mean and range) 1,542 (453–
4,128)
Haemoglobin (mmol/L, ref. M: 8.2–11.0,
F: 7.3–9.7)
8.52±0.83
Haematocrit fraction (ref. M: 0.41–0.52,
F: 0.36–0.48)
0.41±0.04
ALAT (units/L, ref. M: <45, F: <35) 24±13
ASAT (units/L, ref. M: <35, F: <30) 17±10
Serum albumin (g/L, ref. 34–45) 37.0±3.84
Serum creatinine (μmol/L, ref. M: 71–110,
F: 53–97)
128±29
Creatinine clearance (Cockcroft-Gault; mL/min,
ref. 90–140)
58.4±26.6
Ref. are the reference values applied in the Clinical Chemistry and
Haematology Laboratory of the University Hospital in Maastricht. M
Male, F female, MMF mycophenolate mofetil
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12-h time tacrolimus concentration curve. The study was
performed in accordance with the Declaration of Helsinki
and its amendments. The protocol was approved by the
local Medical Ethics Committee and written informed
consent for participation in this study was obtained from
all patients.
Determination of tacrolimus concentrations
The tacrolimus blood concentrations were determined in
ethylene diamine tetra-acetic acid (EDTA) whole blood,
using a method based on high-pressure liquid chromatog-
raphy tandem mass spectrometry (HPLC-MS/MS). The
assay is linear from 1 to 300 μg/l. Intra-assay precision and
accuracy were 3.4, 2.2, and 3.0% and 102, 94 and 94%
respectively at 3.04, 6.23 and 13.0 μg/l (n=6). Inter-assay
precision and accuracy were 8.2, 5.2, and 4.6% and 102, 94
and 93% (n=9) respectively. Lower limit of quantification
was 1.0 μg/l. The laboratory participates in the Internation-
al Tacrolimus Proficiency Testing Scheme.
Limited sampling strategies investigated
In our opinion, a suitable limited sampling strategy for
tacrolimus should consist of two or three time concentration
points within a short time post-dose (≤4 h) including a
trough level. We selected 24 LLS from the literature [12,
15, 16, 18, 20, 22]. Eighteen of these strategies were based
on regression analysis [12, 16, 18, 20, 22], and six other
strategies were based on Bayesian fitting [15]. Also
strategies based on the tacrolimus C0 and C12 concen-
trations were developed for our own renal transplant patient
population and compared with above-mentioned LSS.
Pharmacokinetics and statistical analysis
The area under the tacrolimus time concentration curve
(AUC0–12) was calculated from the time versus tacrolimus
concentration plot using the linear trapezoidal rule in
MWPharm 3.50 (Mediware, Groningen, The Netherlands).
The predicted AUC0–12 (AUCpred), calculated with the 24
different LSS, were validated by determining the predictive
performance as described by Sheiner and Beal [24]. The
percentage of the prediction error (PE) and the percentage
of the absolute prediction error (APE) are parameters often
used for validation in LSS [12, 14–16, 18, 20, 22]. Given
the high pharmacokinetic variability, an APE of less than
15% was considered clinically acceptable [16, 25, 26].
Prediction bias was measured as a percentage of the
prediction error [PE (%)] using the following formula:
PE % ðÞ ¼ 100   AUCpred   AUCactual
 
AUCactual
Prediction precision was measured as a percentage of the
APE using the following formula:
APE % ðÞ ¼ 100   AUCpred   AUCactual
    
AUCactual
The variance in the strength of association between the
AUCpred and the AUCactual was reflected by the linear
regression coefficient of multiple determination (R
2). All
values are expressed as mean±SD. All statistical analyses
were performed with use of SPSS 12.0 software for
windows (Chicago, IL, USA).
Results
Evaluation of predictive performances of the limited
sampling strategies
Table 2 shows an overview of the studies describing the
LSS evaluated in the present study. The regression
equations and the R
2 found by the investigators for the
evaluated LSS are summarised in Table 3. Table 4 describes
the R
2, which represents the association between AUCpred
and AUCactual and the calculated PE and APE of the 24
evaluated LSS for our 37 pharmacokinetic profiles. Thir-
teen of the 18 LSS (72%) based on regression analysis had
a predictivity of >90%. Additionally, all except three of the
LSS examined gave a better prediction of the complete
AUC0–12 in comparison with LSS based on a trough
concentration C0 and C12 (mean 62%). Predictivity of all
six LSS based on Bayesian fitting was <90% (mean
66.8%). Additionally, Fig. 1 illustrates an overview of the
performances of the 26 LSS evaluated in our well-
characterized population of renal transplant recipients.
Discussion
Our results confirm the results of several other studies [12,
14–16, 18, 20, 22] that trough concentrations C0 and C12
have a lower predictive value for the complete 12-h AUC
than almost all other studied LSS. The predictivity of LSS
based on Bayesian estimation of the AUCactual was lower
than the LSS based on regression analysis. Therefore a
trough level and one or two time points in the early phase
(≤4 h) post-dose seem not to be sufficient for a Bayesian
estimation strategy to fit correctly most of the AUC0–12 and
thus predict the complete AUC0–12 reliably. The differences
in variability and shape between the curves of post-
transplant recipients combined with just two or three
sample points might have been caused by the large
differences found between the AUCpred calculated accord-
ing to the Bayesian estimation strategy and the complete
AUCactual.
Eur J Clin Pharmacol (2007) 63:1039–1044 1041In contrast to most studies that describe LSS for
tacrolimus in literature, we used an HPLC-MS/MS assay
to determine the tacrolimus concentration. Because there
seems to be a fixed difference of about 15% between the
immunoassay and the HPLC-MS/MS, the prediction will
change proportionally, and the predictivity of the LSS will
be the same. Also potential interfering drug-drug interac-
tions will have an equal influence on the different
Table 3 Overview of limited sampling strategies and their reported coefficients of correlation (R
2) with the complete tacrolimus AUC0–12
Equation Time points Regression equations R
2 Ref
1. C0 14:550 þ 13:387   C0 0.54
2. C12 15:892 þ 17:852   C12 0.79
3.
a C0,C 2,C 4 13:3 þ 1:2   C0 þ 2:4   C2 þ 5:6   C4 0.93 [16]
4.
a C2,C 4 16:2 þ 2:4   C2 þ 5:9   C4 0.93 [16]
5.
a C0,C 2,C 4 0:98 þ 4:17   C0 þ 2:29   C2 þ 5:3   C4 0.97 [20]
6. C0,C 4 3:75 þ 5:52   C0 þ 6:97   C4 0.95 [20]
7. C0,C 1,C 2  5:496 þ 7:189   C0 þ 2:357   C1 þ 2:131   C2 0.93 [18]
8.
a C0,C 1,C 4 3:85 þ 3:688   C0 þ 1:355   C1 þ 6:649   C4 0.97 [18]
9.
a C0,C 2,C 4  6:103 þ 2:383   C0 þ 1:911   C2 þ 7:582   C4 0.97 [18]
10.
a C1,C 2,C 4 1:304 þ 0:465   C1 þ 1:636   C2 þ 8:256   C4 0.96 [18]
11. C0,C 1 9:345 þ 8:408   C0 þ 3:23   C1 0.91 [18]
12.
a C0,C 4 8:231 þ 2:316   C0 þ 9:636   C4 0.95 [18]
13.
a C1,C 4 13:114 þ 0:873   C1 þ 9:291   C4 0.95 [18]
14.
a C2,C 4  0:192 þ 1:888   C2 þ 8:783   C4 0.96 [18]
15.
a,b C0,C 1,C 4 4:5   C0 þ 2   C1 þ 5:5   C4 0.97 [18]
16.
a,b C0,C 2,C 4 5   C0 þ 2   C2 þ 5   C4 0.96 [18]
17. C0,C 1,C 4 8:90 þ 4:0   C0 þ 1:77   C1 þ 5:47   C4 0.97 [12]
18. C0,C 1,C 3 Bayesian estimation of the actual AUC0–12 0.97 [15]
19. C0,C 2,C 3 Bayesian estimation of the actual AUC0–12 0.96 [15]
20. C0,C 2,C 4 Bayesian estimation of the actual AUC0–12 0.97 [15]
21. C0,C 2 Bayesian estimation of the actual AUC0–12 0.94 [15]
22. C0,C 3 Bayesian estimation of the actual AUC0–12 0.96 [15]
23. C0,C 4 Bayesian estimation of the actual AUC0–12 0.95 [15]
24.
a C0,C 2,C 4 5:87 þ 4:50   C0 þ 1:05   C2 þ 5:87   C4 0.98 [22]
25. C0,C 4 1:16 þ 4:41   C0 þ 7:71   C4 0.96 [22]
26.
a C2,C 4 24:36 þ 0:97   C2 þ 7:94   C4 0.94 [22]
Limited sample strategies derived from the linear trapezoidal rule and the complete 12-h AUC.
aLimited sampling strategies that are able to predict 90% of complete AUC0–12 of the renal transplant recipients within the absolute prediction
error (APE) of 15%.
bLimited sample strategies derived from the linear trapezoidal rule and the actual AUC0–12.
Table 2 Overview of the characteristics of transplant patients included in the studies that described limited sampling strategies
Study Transplanted organ Number
of patients
a
Number of AUC0–12
curves for validation (I
b/NI
c)
Analytical
method
d
Time since
transplantation
e
Inclusion
criteria
f
Wong et al. [16] Kidney 18 0/18 Imx II 2.5 years 1,2
Aumente Rubio et al. [20] Heart 22 0/25 Imx <1 year –
Pisitkun et al. [18] Kidney 15 0/15 Imx II 8.7 months 1,2,3
Armendariz et al. [12] Kidney 22 13/14 Imx Unknown –
Scholten et al. [15] Kidney 43 64/20 Imx Differs
g 2
Ragette et al. [22] Lung 15 0/31 Imx 7.3 months –
aNumber of transplant patients used in the included study for both developing and validating the limited sampling strategies.
bNumber of AUC0–12 used for developing the limited sampling strategies.
cNumber of independent (I) and dependent (NI) AUC0–12 used in the study to validate the created limited sampling strategies.
dThe analytical method used to determine the whole blood tacrolimus concentration.
eThe mean time after transplantation.
fThe inclusion criteria used for the transplant patients in the different studies. 1 Tacrolimus administrated when patients were in the fasting state, 2
patients selected for using no interfering medication with tacrolimus, 3 patients selected with a normal liver function test.
gTwenty-two pharmacokinetic profiles were obtained within 2 weeks after transplantation, and 42 pharmacokinetic profiles were obtained
between 6 and 52 weeks after transplantation.
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effect on the predictivity of the different LSS.
Ting et al. [23] recently suggested that LSS should only
b ea p p l i e do nt r a n s p l a n tp a tient populations that are
comparable with the transplant patient population that was
used to develop the LSS. However, the renal transplant
patient group examined in the present study was not exactly
comparable with the transplant patient populations in which
the equations for the LSS were developed. For example
Aumente Rubio et al. [20] and Ragette et al. [22] used heart
and lung transplant recipients respectively to develop and
validate their LSS. Despite the fact that the LSS were
developed with the pharmacokinetic profiles of patients
who underwent a different kind of transplantation, Eqs. (5),
(24) and (26) were able to predict at least 90% of the
AUC0–12 within an APE of 15%, which suggests that these
LSS are more robust than expected by Ting et al. [23]. Even
though LSS gave a better reflection of the tacrolimus
exposure, they are currently not often applied by clinical
transplant practioners, possibly for logistical and financial
reasons.
Fig. 1 An overview of the predictive performances of the limited
sampling strategies published using 37 different pharmacokinetic
profiles recorded in our renal transplant recipients. The number of
limited sampling strategies categorized into the percentage of AUC0–12
within a prediction error of <15% is plotted on the x-axis, the number
of limited sampling strategies is plotted on the y-axis
Table 4 Evaluation of predictive performance of limited sampling strategies to estimate the complete AUC0–12 in the 37 renal transplant
recipients
Equation Time points R
2 Mean PE (%) Mean APE (%) ≤15%
a
23.
b C0,C 4** 0.760 −14.9±13.8 (−46.0–33.2) 17.9±9.43 (1.12–46.0) 13 (35%)
22.
b C0,C 3** 0.779 −11.5±14.0 (−41.9 to 33.1) 15.7±8.83 (2.0–41.9) 21 (57%)
1. C0 0.536 2.11±14.8 (−27.1 to 24.4) 12.3±8.22 (0.7–27.1) 22 (59%)
11. C0,C 1 0.703 6.58±14.8 (−26.5 to 43.7) 12.6±10.1 (0.1–43.7) 24 (65%)
2. C12 0.80 9.56±11.6 (−12.7 to 29.9) 12.0±8.97 (0.3–29.9) 24 (65%)
19.
b C0,C 2,C 3** 0.502 −4.44±17.4 (−45.3 to 50.6) 13.7±11.4 (0.4–50.6) 25 (68%)
20.
b C0,C 2,C 4** 0.537 −5.11±16.3 (−43.1 to 50.3) 12.9±10.4 (0.2–50.3) 28 (76%)
18.
b C0,C 1,C 3** 0.525 9.95±19.4 (−29.7 to 88.8) 13.1±17.4 (0.4–88.8) 30 (81%)
25. C0,C 4 0.911 −7.83±6.36 (−21.3 to 2.4) 8.08±6.02 (0.1–21.3) 30 (81%)
7. C0,C 1,C 2 0.869 2.35±9.96 (−17.2 to 27.3) 8.03±6.22 (0.0–27.3) 31 (84%)
6. C0,C 4 0.896 −5.97±6.71 (−20.1 to 4.7) 6.63±6.04 (0.6–20.1) 31 (84%)
21.
b C0,C 2** 0.802 −3.69±10.2 (−19.6 to 18.6) 9.10±5.67 (0.4–19.6) 31 (84%)
17. C0,C 1,C 4 0.943 5.91±7.06 (−8.8 to 26.3) 7.02±5.93 (0.2–26.3) 33 (89%)
15.
c C0,C 1,C 4* 0.934 5.00±7.28 (−9.8 to 25.8) 6.81±5.57 (0.2–25.8) 34 (92%)
14. C2,C 4 0.964 2.28±6.58 (−17.1 to 16.1) 5.45±4.24 (0.7–17.1) 35 (95%)
24. C0,C 2,C 4 0.941 −4.81±5.26 (−17.3 to 2.8) 5.32±4.73 (0.1–17.3) 35 (95%)
13. C1,C 4 0.973 6.30±4.84 (−5.9 to 17.8) 6.68±4.28 (0.3–17.8) 36 (97%)
8. C0,C 1,C 4 0.967 3.37±5.21 (−5.2 to 17.7) 4.87±3.80 (0.2–17.7) 36 (97%)
9. C0,C 2,C 4 0.962 0.10±6.37 (−16.7 to 14.7) 4.71±4.22 (0.3–16.7) 36 (97%)
26. C2,C 4 0.959 3.38±5.24 (−7.6 to 15.5) 5.20±3.37 (0.0–15.5) 36 (97%)
10. C1,C 2,C 4 0.976 3.07±5.40 (−14.9 to 13.2) 4.99±3.64 (0.1–14.9) 37 (100%)
16.
c C0,C 2,C 4* 0.953 −1.58±5.29 (−14.9 to 10.1) 4.00±3.75 (0.0–14.9) 37 (100%)
12. C0,C 4 0.930 3.55±6.30 (−9.8 to 14.3) 6.29±3.46 (0.1–14.3) 37 (100%)
4. C2,C 4 0.963 −1.66±4.99 (−12.0 to 14.3) 4.13±3.20 (0.2–14.3) 37 (100%)
5. C0,C 2,C 4 0.959 1.33±5.24 (−11.8 to 14.0) 4.22±3.32 (0.5–14.0) 37 (100%)
3. C0,C 2,C 4 0.965 −0.20±4.79 (−10.4 to 13.7) 3.64±3.06 (0.2–13.7) 37 (100%)
aNumber and percentage of calculated AUC0–12 with a prediction error within 15%.
bBayesian estimation of the actual AUC0–12.
cLimited sample strategies derived from the linear trapezoidal rule and the actual AUC0–12.
Eur J Clin Pharmacol (2007) 63:1039–1044 1043In conclusion, after validating several LSS from the
literature, the present study indicates that all but three LSS
gave a better prediction of the complete AUC0–12 than the
trough concentrations C0 or C12. Moreover, LSS could
produce satisfactory predictions for AUC0–12 recorded in an
independent renal transplant patient population, although
further evaluation of their reliability is necessary.
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